Intra-Cellular Therapies ...

NASDAQ: ITCI · Real-Time Price · USD
131.87
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM

Intra-Cellular Therapies Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
306.95M 147.77M 148.62M 92.36M
Short-Term Investments
694.12M 350.17M 443.29M 319.97M
Long-Term Investments
n/a n/a n/a n/a
Other Long-Term Assets
44.65M 45.91M 86K 86.08K
Receivables
166.5M 114.02M 75.19M 20.16M
Inventory
26.28M 11.65M 23.92M 7.95M
Other Current Assets
113.52M 44.19M 46.94M 10.9M
Total Current Assets
1.31B 667.8M 737.96M 467.28M
Property-Plant & Equipment
14.9M 14.58M 16.74M 22.56M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
59.55M 60.5M 16.82M 22.64M
Total Assets
1.37B 728.29M 754.78M 489.92M
Account Payables
26.07M 11.45M 10.39M 8.69M
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
4.23M n/a 4.57M n/a
Other Current Liabilities
175.4M 81.12M 40.71M -522
Total Current Liabilities
205.7M 123.55M 83.24M 53.36M
Long-Term Debt
12.75M n/a n/a 18.67B
Other Long-Term Liabilities
n/a n/a n/a -18.67B
Total Long-Term Liabilities
12.75M 13.33M 15.47M 18.67M
Total Liabilities
218.45M 136.87M 98.71M 72.03M
Total Debt
16.98M 16.94M 20.04M 25.41M
Common Stock
11K 10K 9K 8.19K
Retained Earnings
-1.69B -1.62B -1.48B -1.22B
Comprehensive Income
191K 104K -4.19M -363.65K
Shareholders Equity
1.15B 591.42M 656.07M 417.89M
Total Investments
694.12M 350.17M 443.29M 319.97M